Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Loading
Search
Results
3 stories for“triple agonist obesity”
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
